Seán Barry

Over recent years, an increasing number of medicines have been developed for orphan indications and for treatment of unmet clinical need. The abbreviated development times associated with such clinical programmes has required sponsors to expedite CMC activities…

Accelerated CMC and regulatory efficiency tools can be used to support the approval of medicines in early access programmes, such as emergency medicines and medicinal products for unmet medical need…